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Abstract
Objective: To compare the cost effectiveness of two
possible modifications to the current UK screening
programme: shortening the screening interval from
three to two years and extending the age of invitation
to a final screen from 64 to 69.
Design: Computer simulation model which first
simulates life histories for women in the absence of a
screening programme for breast cancer and then
assesses how these life histories would be changed by
introducing different screening policies. The model
was informed by screening and cost data from the
NHS breast screening programme.
Setting: North West region of England.
Main outcome measures: Numbers of deaths
prevented, life years gained, and costs.
Results: Compared with the current breast screening
programme both modifications would increase the
number of deaths prevented and the number of life
years saved. The current screening policy costs £2522
per life year gained; extending the age range of the
programme would cost £2612 and shortening the
interval £2709 per life year gained. The marginal cost
per life year gained of extending the age range of the
screening programme is £2990 and of shortening the
screening interval is £3545.
Conclusions: If the budget for the NHS breast
screening programme were to allow for two more
invitations per woman, substantial mortality
reductions would follow from extending the age
range screened or reducing the screening interval.
The difference between the two policies is so small
that either could be chosen.
Introduction
In 1988 the NHS breast screening programme, on the
recommendation of an expert committee, began
screening women aged 50›64 years every three years.
However, the committee also concluded that the
optimum frequency of screening and the age range
likely to benefit from breast screening were still
undetermined.1 We used the computer simulation
package Microsimulation Screening Analysis (MIS›
CAN) to compare the cost effectiveness of two possible
modifications to the current UK screening pro›
gramme: shortening the screening interval from three
to two years and extending the age of invitation to a
final screen from 64 to 69.
Methods
A full description of the Microsimulation Screening
Analysis model has been published.2 In brief, the model
first simulates life histories for women in the absence of
a screening programme for breast cancer and then
assesses how these life histories would change as a con›
sequence of introducing different screening policies.
The natural course of breast cancer is modelled as
a progression from no breast cancer through preclini›
cal cancer to clinical disease. Women reside in the first
state (no breast cancer) before entering one of five pre›
clinical states. There is an in situ state and four invasive
states according to the tumour size (T state): <5 mm
(T1a), > 5›10 mm (T1b), > 10›20 mm (T1c), and
> 20 mm (T2 + ). A cancer may be detected at screen›
ing, become clinically apparent in any one of these
states, or if undiagnosed progress to the next preclini›
cal state. The two end states of the model are death
from breast cancer and death from other causes.
The model was set up using data from the Dutch
screening trials at Utrecht and Nijmegen to provide
estimates of the mean duration of the preclinical phase
for women in different age groups and the mean dura›
tion of cancer in each of the five preclinical states. The
dwelling time of a cancer in each preclinical state is
assumed to follow an exponential distribution, and the
rate at which cancers progress from the preclinical to
the clinical state is inferred from the observed
incidence and distribution of stages of clinically
diagnosed cancers in the population being studied.
When modelling the performance of a screening
programme, key indicators include the mean duration
of the screen detectable phase, the sensitivity of the test,
and the improvement in prognosis for screen detected
cancers. The mean preclinical screen detectable period
assumed in the model was based on data from the
Dutch screening projects at Nijmegen and Utrecht and
varied from 1.8 years at age 35 to 6.2 years at age 70.
The sensitivity of the screening test is assumed in
the model to be the probability of detecting a cancer in
the preclinical screen detectable state. For women aged
over 50 it is fixed as 0.4, 0.65, 0.8, 0.9, and 0.95 for in
situ disease, T1a, T1b, T1c, and T2 + tumours
respectively. The improvement in prognosis for screen
detected cancers was derived from the results of the
Swedish breast screening trials.3
Applying model to UK population
The North West health region has a population of 4.1
million and is covered by five NHS breast screening
programmes. The largest of these, the Manchester
breast screening programme, has screened over
120 000 women and reported cancer detection rates
similar to those elsewhere in the United Kingdom.4
The number and size of cancers detected at a first and
second screen and the occurrence and size of interval
cancers in this programme have been used to inform
the model. Estimates of screening and diagnostic costs
are based on this programme assuming that two view
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mammography is used at the first screen and single view
mammography at subsequent screens. Treatment costs
are derived from various sources, but primarily the
Christie Hospital NHS Trust in Manchester. Full details
of the costing, including sensitivity analysis, have been
published.5 Both costs and effects are discounted at 6%.
To simulate the life histories of women with breast
cancer before a screening programme is introduced
the model requires information on the age, distribu›
tion of stage, and survival of women with breast cancer.
Neither the prescreening distribution of stage nor
stage specific survival rates before screening was intro›
duced were available for the North West’s population.
However, the prescreening stage distribution in
Scotland6 and in East Anglia (J McCann, East Anglian
Cancer Registry, personal communication) was similar
to that of the control population in the Utrecht screen›
ing trial. We therefore assumed that the prescreening
stage distribution in the North West was similar to that
used in setting up the computer model. The stage dis›
tribution in women aged 50›69 at diagnosis in the
Utrecht control population was: 4.6% in situ, 1.5% T1a,
6.3% T1b, 32.6% T1c, and 55% T2 + . Having assumed
this stage distribution, we derived stage and age specific
survival rates by fitting the North West’s observed mor›
tality for 1987 to the observed incidence for 1987. This
produced an overall five year survival for women aged
50›59 and women aged 60›69 of 67% and 68% respec›
tively. A life table describing the probability of dying
from causes other than breast cancer in the North West
was used to derive the number of life years gained per
breast cancer death prevented.
The model was unable to simulate the detection
rate and distribution of stages observed at first screen›
ing in the North West. More small cancers were
observed in the North West than were predicted by the
model. This discrepancy was resolved by assuming a
longer screen detectable preclinical phase for small
tumours. When it was assumed that small tumours (less
than 10 mm) dwelt in a screen detectable phase for
twice as long as that used in the initial set up, the model
adequately fitted the detection rate and stage distribu›
tion observed at first screening in the North West.
This model was used to simulate the effects and costs
of three screening programmes for the North West:
firstly, the current UK screening policy, in which women
aged between 50 and 64 are invited for screening every
three years; secondly, screening every three years but
extending the age of women screened from 64 to 69
years; and, finally, reducing the screening interval from
three to two years while maintaining the current age
range. Attendance for screening was assumed to fall by
0.5% for each year of age, from 74.2% at age 50 to 67.9%
at age 70; attendance at repeat invitations was assumed
to be 78% higher than among those who attended the
previous invitation. Each screening programme was
assumed to run for 27 years.
Results
The final model adequately predicted the rates of
screen detected cancers observed at the first and
second screening round, the distribution of stages
observed at the first screen but not the distribution
observed at the second screen, and the interval cancer
rates observed after a first screen (tables 1›3).
Table 4 provides a summary of the costs and effects
of the three screening policies compared with no
screening. This suggests that the current North West
screening programme reduces mortality by 12.8%,
preventing 4079 deaths over 27 years; this is equivalent
to 66 187 life years gained or 12 251 life years
discounted to present values.
Screening to age 69 reduced mortality by 16.4%,
preventing 5311 deaths over 27 years (equivalent to
Table 1 Observed and computer modelled rates of detection of
breast cancer per 1000 women screened
Age
First screening Second screening
Observed Modelled Observed Modelled
50›54 5.5 4.6 NA 3.7
55›59 5.6 5.6 NA 4.0
60›64 7.1 7.6 NA 5.5
All ages 6.0 5.9 4.7 4.6
NA=not available.
Table 2 Observed and computer modelled distribution of
tumour stage (T state). Values are percentages of women
Stage
First screening Second screening
Observed Modelled Observed Modelled
In situ 14.2 14.9 17.0 15.1
T1a 8.6 9.1 3.8 13.0
T1b 31.5 31.0 29.6 38.8
T1c 31.0 30.2 33.9 25.6
T2+ 14.7 14.8 15.7 7.5
Table 3 Observed and computer modelled rates of interval
cancer after first screening per 10 000 women screened
Months after screen Observed Modelled
0›11 5.5 5.4
12›23 9.2 9.8
24›35 14.9 13.0
Total 29.5 28.2
Table 4 Effects and costs of three screening policies for breast
cancer
Current
programme
Extension to
age 69
Two year
interval
Effectiveness (no discounting)
Reduction in mortality (%)* 12.8 16.4 15.3
Deaths prevented/year* 147 188 175
Total deaths prevented 4 079 5 311 4 880
Life years gained 66 187 78 221 81 322
Costs (£m) (6% discounted)
Screening 26.8 34.7 36.9
Diagnosis (screening) 17.4 21.1 19.7
Diagnosis (outside screening) −11.1 −14.1 −12.9
Primary treatment 6.2 9.1 7.1
Adjuvant therapy −1.5 −2.1 −1.8
Follow up 2.9 4.0 3.5
Advanced disease −9.8 −13.1 −11.8
Total 30.9 39.6 40.6
Effectiveness (6% discounted)
Deaths prevented 1 229 1 636 1 457
Life years gained 12 251 15 161 14 987
Cost effectiveness (6% discounted)
Cost per death prevented (£) 25 142 24 205 27 865
Cost per life year gained (£) 2 522 2 611 2 709
Marginal cost effectiveness/life
year gained (£)
2 990 3 545
*In a steady state.
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78 221 life years gained or 15 161 life years discounted
to present values). A screening interval of two years
reduced mortality by 15.3%, preventing 4880 deaths
(equivalent to 81 322 life years gained or 14 987 life
years discounted to present values).
The cost of the current programme is £30.9
million. This increases to £39.6 million if the age range
of the programme is extended and to £40.6 million if
the screening interval is reduced. Most of the money is
spent on screening and investigation of women
recalled with a suspicious result, but some money is
saved because of the reduced diagnostic and treatment
costs in women who would otherwise have presented
with symptoms.
These data suggest that the cost of a life year gained
by screening when costs and benefits are discounted at
6% (derived by dividing discounted life years gained by
the cost of the programme) is £2522 in the current
programme, £2611 if the age range of the programme
is extended, and £2709 if the screening interval is
shortened. The impact of changing the current screen›
ing policy is best summarised by comparing the
marginal cost effectiveness of the two modified
policies, which is calculated by dividing the difference
in total costs of the current and proposed policies by
the difference in life years gained. The marginal cost
per life year saved of extending the age range of the
screening programme is £2990 and of shortening the
screening interval £3545.
We also conducted the cost effectiveness analysis
using the lower and upper unit cost estimates for
screening, diagnosis, and treatment and different
discount rates. Under all scenarios considered the cur›
rent programme had a lower marginal cost per life
year saved or death prevented than the two other poli›
cies.5 Two other models using different assumptions
about the length of the preclinical detectable phase
and the size distribution of tumours at presentation
were also explored, and the relative outcomes on cost
effectiveness were the same. These models were
rejected, however, because they did not fit all the avail›
able data as adequately as the model described.
Discussion
The computer model was developed and refined at the
Erasmus University, Rotterdam. It has been validated
with data from the Netherlands2 and Sweden,3 assump›
tions underpinning the model have been evaluated by
others,7 and the results from the model have been used
to evaluate screening programmes in several European
countries.8–11 For the model to simulate the detection
rates and distribution of stages observed at first screen›
ing in the North West we had to assume a longer pre›
clinical detectable phase for smaller tumours than was
estimated from the Dutch pilot projects and the Dutch
national screening programme. A longer preclinical
detectable phase is in accordance with a lower thresh›
old of detection of breast cancer at screening.
The model adequately simulated the number of
cancers occurring in the interval between screens and
those detected at a second screen, but it predicted a
better stage distribution at repeat screening than was
observed. This discrepancy has been reported before11
and is being investigated by the Erasmus team. It is
unlikely, however, that the discrepancy substantially
affected the conclusion since a better stage distribution
at repeat screens is modelled in all policy options and
the overall reduction in mortality predicted for each
screening policy option is not greater than the
reductions reported from the randomised trials of
breast screening.
Which is the best policy?
In cost effectiveness analysis of programmes whose
main effect is to extend life the usual measure of ben›
efit is life years gained. Compared with the current
breast screening programme both of the alternatives
evaluated offer improved effectiveness; both are
predicted to increase the number of life years gained
and number of deaths prevented. Choice of policy will
depend on which outcome measure is chosen, whether
discounting is undertaken, and whether costs are con›
sidered. If health effects are not discounted and costs
are ignored, extending the age range prevents more
deaths but reducing the screening intervals results in
more life years gained.
Whether either of the proposed changes to the
programme is cost effective depends on the value the
NHS is willing to place on improvements in the effec›
tiveness of the programme. Compared with no screen›
ing and assuming a discount rate of 6% applied to all
costs and outcomes the current programme costs
£25 142 per death prevented and £2522 per life year
saved. The cost per life year saved is higher with both
proposed changes, but extending screening to women
aged 69 reduces the cost per death prevented. If cost
per death prevented is taken as the appropriate
outcome measure then extending the age of screening
is more cost effective than the current policy. This
policy also has a smaller increase in cost per life gained
than two year screening compared with the current
programme.
In conclusion, if the budget for the NHS breast
screening programme would allow for two more
invitations per woman, the computer model predicts
that the difference between extending the age range
screened or reducing the screening interval from three
to two years is so small that either could be chosen.
This conclusion was not affected by using upper and
lower estimates of the costs of screening, diagnosis, and
treatment or by varying the discount rate of costs and
benefits.
We thank Luke Readman of the Manchester Breast Screening
Service and Liz Twelves of the North West Regional Breast
Key messages
+ Computer modelling suggested that the current breast screening
programme in North West England will reduce total female breast
cancer mortality by 12.8%
+ Extending the programme to age 69 would reduce mortality by
16.4% at a marginal cost per life year saved of £2990 while
reducing the interval to two years would reduce mortality by 15.3%
at a marginal cost per life year saved of £3545
+ Extending the age range prevents more deaths from breast cancer
but shortening the interval gains more life years
+ If the budget for the NHS breast screening programme would
allow for two more invitations per woman either of the two options
could be chosen
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Safety and toxicity of amphotericin B in glucose 5% or
intralipid 20% in neutropenic patients with pneumonia or
fever of unknown origin: randomised study
Patrick Schöffski, Mathias Freund, R Wunder, D Petersen, C H Köhne, H Hecker, U Schubert,
A Ganser
Abstract
Objective: To compare the feasibility of treatment,
safety, and toxicity of intravenous amphotericin B
deoxycholate prepared in either glucose or intralipid
for empirical antimycotic treatment of neutropenic
cancer patients.
Design: Single centre stratified, randomised
non›blinded phase II study.
Setting: University hospital providing tertiary clinical
care.
Subjects: 51 neutropenic patients (leukaemia (35),
lymphoma (11), solid tumours (5)) with refractory
fever of unknown origin (24) or pneumonia (27).
Interventions: Amphotericin B 0.75 mg/kg/day in
250 ml glucose 5% solution or mixed with 250 ml
intralipid 20%, given on eight consecutive days then
alternate days, as a 1›4 hour infusion.
Main outcome measures: Feasibility of treatment,
subjective tolerance (questionnaire), and objective
toxicity (common toxicity criteria of the National
Cancer Institute).
Results: Study arms were balanced for age, sex,
underlying malignancy, renal and liver function, and
pre› and concomitant treatment with antibiotics and
nephrotoxic agents. No statistically significant or
clinically relevant differences were found between the
treatment groups for: daily or cumulative dose and
duration of treatment with amphotericin B; incidence
and time of dose modifications or infusion duration
changes related to toxicity; dose or duration of
symptomatic support with opiates, antipyretics, or
antihistamines; renal function; subjective tolerance;
most common toxicity scores; course of infection; and
incidence of treatment failures. Patients treated with
amphotericin B in intralipid were given fewer
diuretics (P < 0.05) and therefore had more peripheral
oedema (P < 0.01) and needed less potassium
supplementation (P < 0.05) than patients given
amphotericin in glucose. Acute respiratory events
were more common in the intralipid arm (P < 0.05).
Conclusions: Amphotericin B 0.75 mg/kg/day in
intralipid given on eight consecutive days then
alternate days provides no benefit and is associated
with potential pulmonary side effects possibly because
of fat overload or an incompatibility of the two drugs.
Introduction
Amphotericin B is regarded as the agent of choice for
treatment of life threatening mycoses in neutropenic
patients because of its broad antimycotic activity.1 It is
conventionally given intravenously in glucose 5%, as a
colloidal suspension with the detergent sodium deoxy›
cholate. Amphotericin B is associated with a high inci›
dence of renal toxicity, potassium loss, fever, and chills.
Attempts have been made to overcome its dose
limiting renal toxicity.2 Well tolerated, highly expensive
liposomal formulations are commercially available,
and can be used in patients developing renal toxicity
after exposure to amphotericin B deoxycholate.
Non›liposomal lipid emulsions are also known to
reduce toxic effects of amphotericin in vitro and in vivo
and have been given to patients.3–11 Intralipid, a
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